PharmaCyte Biotech, Inc. (PMCB) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-04-02

PharmaCyte Biotech, Inc. (PMCB) — no SEC Form 4 insider filings recorded in the last 90 days. InsiderAlpha tracks every PMCB SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About PharmaCyte Biotech, Inc. (PMCB)

SEC CIK	0001157075

Recent PMCB Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-01-07	Silverman Joshua	CEO and President	P — Open-market purchase	40.0K	$0.83	$33K	SEC
2026-01-07	SCHECHTER JONATHAN	Director	P — Open-market purchase	20.0K	$0.84	$17K	SEC
2026-01-06	Silverman Joshua	CEO and President	P — Open-market purchase	30.0K	$0.79	$24K	SEC
2026-01-06	SCHECHTER JONATHAN	Director	P — Open-market purchase	20.0K	$0.79	$16K	SEC
2026-01-05	Silverman Joshua	CEO and President	P — Open-market purchase	30.0K	$0.78	$23K	SEC
2026-01-05	SCHECHTER JONATHAN	Director	P — Open-market purchase	20.0K	$0.78	$16K	SEC
2025-12-12	WEINSTEIN ROBERT	Director	A — Grant or award	75.0K	$0.00	—	SEC
2025-12-12	WEINSTEIN ROBERT	Director	F — Tax withholding / forfeiture	33.8K	$1.02	$34K	SEC
2025-12-12	Abecassis Michael M	Director	A — Grant or award	37.5K	$0.00	—	SEC
2025-12-12	WALKER WAYNE REMELL	Director	F — Tax withholding / forfeiture	16.9K	$1.02	$17K	SEC
2025-12-12	WALKER WAYNE REMELL	Director	A — Grant or award	37.5K	$0.00	—	SEC
2025-12-12	Abecassis Michael M	Director	F — Tax withholding / forfeiture	16.9K	$1.02	$17K	SEC
2025-12-12	Silverman Joshua	CEO and President	A — Grant or award	575.0K	$0.00	—	SEC
2025-12-12	Silverman Joshua	CEO and President	F — Tax withholding / forfeiture	258.8K	$1.02	$264K	SEC
2025-12-12	SCHECHTER JONATHAN	Director	A — Grant or award	150.0K	$0.00	—	SEC

All transactions sourced from SEC EDGAR Form 4 filings for PharmaCyte Biotech, Inc. (PMCB). Updated in real time as new filings are submitted to the SEC.

Recent PMCB Form 8-K Material Events

2026-04-02 — Item 5.02, 5.07, 9.01 · Other · neutral [SEC]
PharmaCyte Biotech held its annual stockholders meeting on March 30, 2026, where shareholders approved an amendment to the 2022 Equity Incentive Plan increasing available shares by 2,000,000 shares. Five directors were elected to serve until the next annual meeting. This is a rou

Recent Insider Filings

2026-04-02 — WEINSTEIN ROBERT (Director)
2026-04-02 — WALKER WAYNE REMELL (Director)
2026-04-02 — SCHECHTER JONATHAN (Director)
2026-04-02 — Abecassis Michael M (Director)
2026-01-07 — Silverman Joshua (CEO and President)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in PMCB insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

PMCB Insider Trading — FAQ

What is the latest insider trade for PMCB?: PharmaCyte Biotech, Inc. (PMCB) had 0 insider filings in the last 90 days, with the most recent on 2026-04-02. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying PMCB stock?: 0 insider purchases of PMCB were filed in the last 90 days.
How many insiders are selling PMCB stock?: 0 insider sales of PMCB were filed in the last 90 days.
Where can I see PMCB SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every PMCB SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live PMCB dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.